TIDMAKR
Akers Biosciences, Inc.
08 December 2017
December 8, 2017
Akers Biosciences, Inc.
Further Intellectual Property Protection for Akers Wellness
Line
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, announces that its Health and Wellness product line
is now protected by ten patents in the US, the European Union,
Japan, China and Hong Kong, with additional patents pending in the
European Union and India; and six trademark registrations in the
US.
The patents address three novel areas of technology developed by
Akers Bio for the Company's Akers Wellness(TM) line.
The first group of three patents expand the US protection
already granted to further countries and cover the unique design of
the disposable cartridge which contains the reagent for the
detection of wellness markers in exhaled breath. The reagent
contained within is analyzed using optical scanning technology
after contact with the user's breath sample and produces a
quantitative result through the Akers Wellness(TM) app on the
user's smartphone or tablet. Included in the patent group are the
unique form factor, optical lens and read elements and the unique
'U' shaped airflow pathway.
A second group of three patents cover the Company's BreathScan
Lync(TM) technology. BreathScan Lync(TM) is the new
bluetooth-enabled reading device from Akers Wellness(TM) which
enables users to track the results of Akers Wellness(TM)
breath-based tests via their mobile device.
A third group of four patents cover the device and apparatus
used to determine levels of ketones in exhaled breath indicative of
ketosis, an optimal fat-burning state for weight loss.
Akers Wellness(TM) breath tests, such as BreathScan OxiChek(TM)
and BreathScan KetoChek(TM), are designed to help promote, track
and/or encourage choices related to general health and wellbeing;
to achieve an optimal metabolic state for fitness or endurance
events; or to support weight loss. Unlike current laboratory
testing methods that use an invasive blood draw - and have a
turnaround time of 7 to 10 days - Akers Bio's rapid tests work with
a person's exhaled breath in just a few minutes.
BreathScan OxiChek(TM) is the first disposable breath test to
rapidly determine levels of oxidative stress in the body by
measuring the levels of certain free radicals, such as hydrogen
peroxide. Frequent use of BreathScan OxiChek(TM) may help health
practitioners, such as anti-aging, functional and integrative
health and wellness consultants, nutritionists, chiropractors and
fitness coaches to monitor and adjust their clients' regimen of
diet, exercise and nutritional supplementation in order to manage
oxidative stress - an indicator of the overall health and wellbeing
of a person.
The BreathScan KetoChek(TM) test rapidly determines if the
subject is in the optimal fat-burning state for weight loss, known
as ketosis. Achieving a state of ketosis - as indicated by the
measure of breath ketones - is a goal of many individuals following
low carbohydrate diets. BreathScan KetoChek(TM) is a simple,
non-invasive test to identify, track and quantitatively monitor
breath ketones for individuals interested in achieving an optimal
metabolic state for fitness or endurance events, or for maximizing
weight loss.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented: "We are very pleased to announce that Akers Bio has
successfully expanded its intellectual property position. These
initiatives further support our strategic goal of delivering
innovative, pioneering and transformational products that exceed
customer expectations and contribute profitable growth for the
company."
Raymond F. Akers, Jr. PhD, Executive Chairman and Chief
Scientific Director of Akers Bio, commented: "Akers Wellness(TM) is
dedicated to improving the health and wellbeing of its customers
and we believe that BreathScan OxiChek(TM) and BreathScan KetoChek
will have a significant impact on this goal. We are pleased that
the intellectual property of these key products of our future is
very well protected."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Executive Chairman and Chief
Scientific Director
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKFDBPBDDKBK
(END) Dow Jones Newswires
December 08, 2017 10:30 ET (15:30 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024